Premium listings
  • 3rd International Conference on Transcriptomics

    3rd International Conference on Transcriptomics

    Life Sciences Bangkok (Bangkok) March 13, 2017 Check with publisher

    Conference Series has been instrumental in conducting international Biochemistry meetings for seven years, and very excited to expand Europe, America and Asia Pacific continents. Previous meetings were held in major cities like Philadelphia, Orlando ...

  • Developing drugs for the treatment of neurodegenerative diseases

    Developing drugs for the treatment of neurodegenerative diseases

    PhD Studentships Liverpool December 3, 2016 Check with publisher

    Ageing is arguably the major biomedical challenge of the 21st century with the incidence of age-related diseases, and neurodegenerative diseases in particular, expected to increase dramatically in the coming decades. In model organisms, the process o...

  • DrugAge database of compounds that increase lifespan

    DrugAge database of compounds that increase lifespan

    Biomedical Sciences Liverpool August 24, 2015 Check with publisher

    We're starting a new database of drugs and compounds (including natural products) with anti-ageing properties that extend longevity in model organisms. The database will be called DrugAge, and although we have some data already, we are looking for da...

Listings
  • How to Accurate Adverse Event Reporting

    How to Accurate Adverse Event Reporting

    Training and Teaching Fremont (California) December 8, 2017 150.00 Dollar US$

    Overview: Learn why the single most important function of the Principal Investigator and the study conduct team is the awareness, assessment, and management of Adverse Events occurring during the conduct of clinical research with drugs or devices uti...

  • Anti-EpCAM-sulfo-SPDB-DM4 ADC

    Anti-EpCAM-sulfo-SPDB-DM4 ADC

    Drug Development Shirley (New York) November 29, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-EpCAM monoclonal antibody conjugated via a sulfo-SPDB linker to DM4. The DM4 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the ce...

  • Anti-EpCAM-SPDB-DM4 ADC

    Anti-EpCAM-SPDB-DM4 ADC

    Drug Development Shirley (New York) November 29, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-EpCAM monoclonal antibody conjugated via a SPDB linker to DM4. The DM4 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, DM...

  • Anti-EpCAM-SMCC-DM1 ADC

    Anti-EpCAM-SMCC-DM1 ADC

    Drug Development Shirley (New York) November 29, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-EpCAM monoclonal antibody conjugated via a SMCC linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, DM...

  • Anti-EGFR (cetuximab)-SMCC-Doxorubicin ADC

    Anti-EGFR (cetuximab)-SMCC-Doxorubicin ADC

    Drug Development Shirley (New York) November 29, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-EGFR monoclonal antibody (cetuximab) conjugated via a SMCC linker to Doxorubicin. The Doxorubicin is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endoc...

  • Anti-EGFR-SMCC-Dox ADC

    Anti-EGFR-SMCC-Dox ADC

    Drug Development Shirley (New York) November 29, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-EGFR monoclonal antibody conjugated via a SMCC linker to Dox. The Dox is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, Dox...

  • Anti-EGFR-SMCC-DM1 ADC

    Anti-EGFR-SMCC-DM1 ADC

    Drug Development Shirley (New York) November 29, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-EGFRvIII monoclonal antibody conjugated via a SMCC linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell,...

  • Anti-EGFR (J2898A)-SMCC-DM1 ADC

    Anti-EGFR (J2898A)-SMCC-DM1 ADC

    Drug Development Shirley (New York) November 29, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-EGFR (J2898A) monoclonal antibody conjugated via a SMCC linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the ...

  • Anti-EGFR (J2898A)-SMCC-DM1 ADC

    Anti-EGFR (J2898A)-SMCC-DM1 ADC

    Drug Development Shirley (New York) November 29, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-EGFR (J2898A) monoclonal antibody conjugated via a SMCC linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the ...

  • Anti-EGFR (MAb806)-SMCC-DM1 ADC

    Anti-EGFR (MAb806)-SMCC-DM1 ADC

    Drug Development Shirley (New York) November 29, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-EGFR monoclonal antibody (MAb806) conjugated via a SMCC linker to a DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within th...

  • Anti-EFNA4 (clone huE47)-AcBut-CM ADC

    Anti-EFNA4 (clone huE47)-AcBut-CM ADC

    Drug Development Shirley (New York) November 29, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-EFNA4 monoclonal antibody (clone huE47)) conjugated via an AcBut linker to CM. The CM is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Disu...

  • Anti-EFNA4 (clone huE22)-AcBut-CM ADC

    Anti-EFNA4 (clone huE22)-AcBut-CM ADC

    Drug Development Shirley (New York) November 29, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-EFNA4 monoclonal antibody (clone huE22)) conjugated via an AcBut linker to CM. The CM is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Disu...